###begin article-title 0
Gene expression changes in response to E2F1 activation
###end article-title 0
###begin p 1
To whom correspondence should be addressed. Tel: +49 201 723 3158; Fax: +49 201 723 5974; Email: brigitte.puetzer@uni-essen.de The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
###end p 1
###begin p 2
###xml 172 177 <span type="species:ncbi:9606">human</span>
The p16/RB/E2F regulatory pathway, which controls transit through the G1 restriction point of the cell cycle, is one of the most frequent targets of genetic alterations in human cancer. Any of these alterations results in the deregulated expression of the transcription factor E2F, one of the key mediators of cell cycle progression. Under these conditions, E2F1 also participates in the induction of apoptosis by a p53-dependent pathway, and independently of p53. Recently, we identified the p53-homolog p73 as a first direct target of p53-independent apoptosis. Here, we used a cDNA microarray to screen an inducible E2F1-expressing Saos-2 cell line for E2F1 target genes. Expression analysis by cDNA microarray and RT-PCR revealed novel E2F1 target genes involved in E2F1-regulated cellular functions such as cell cycle control, DNA replication and apoptosis. In addition, the identification of novel E2F1 target genes participating in the processes of angiogenesis, invasion and metastasis supports the view that E2F1 plays a central role in many aspects of cancer development. These results provide new insight into the role of E2F1 in tumorigenesis as a basis for the development of novel anti-cancer therapeutics.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c1">1</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c2">2</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c3">3</xref>
###xml 918 923 918 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 987 988 987 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c3">3</xref>
###xml 989 990 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c5">5</xref>
###xml 1230 1231 1230 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 1232 1233 1232 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 1350 1351 1350 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c9">9</xref>
###xml 1458 1460 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c10">10</xref>
###xml 797 802 <span type="species:ncbi:9606">human</span>
The balance between cell survival and cell death is critical for many aspects of the homeostasis of multicellular organisms. Compared with normal cells, tumor cells show a loss of these regulatory functions, which results in uncontrolled proliferation and genetic instability (1). In mammalian cells, the decision of whether to undergo DNA synthesis or to stop cell proliferation is made at the G1/S phase transition of the cell cycle (2). A number of cellular proteins such as the positively acting cyclins and cyclin-dependent kinases (CDKs), or the negatively acting cyclin-dependent kinase inhibitors (CDKIs) govern cell cycle progression by controlling the activity of the retinoblastoma (RB) protein through phosphorylation (3). Consistent with its role as a tumor suppressor, virtually all human cancers are associated with alterations in the RB pathway, either through inactivation of RB itself or the CDKI p16INK4a, or through overexpression of cyclin D1 and CDK4 oncoproteins (3-5). In this pathway, the E2F transcription factor is a key downstream target of RB. Hypophosphorylated RB binds E2F and thereby down-regulates E2F activity, suggesting a model in which RB restricts cell cycle progression by restraining E2F (6-8). In fact, the interaction of RB with E2F correlates with the capacity of RB to arrest cell growth in the G1 phase (9). On the other hand, loss of RB-mediated control of E2F activity leads to progression into DNA synthesis (10).
###end p 4
###begin p 5
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DHFR</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORC1</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC6</italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC2</italic>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC25A</italic>
###xml 297 299 297 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB</italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Myc</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-Myb</italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F-1</italic>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F-2</italic>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c11">11</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c12">12</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c13">13</xref>
###xml 999 1007 999 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c14">14</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c15">15</xref>
E2F DNA-binding sites have been identified in the promoter regions of many genes involved in DNA replication [e.g. dihydrofolate reductase (DHFR), DNA polymerase, thymidine kinase, thymidylate synthetase, ORC1 and CDC6] and cell cycle control [e.g. cyclin E (CCNE1), cyclin A, CDC2, CDC25A, p107, RB, c-Myc, N-Myc, B-Myb, E2F-1 and E2F-2] (8,11). So far, six members of the E2F family, E2F1-E2F6, have been cloned and molecularly characterized (12). All of them contain highly conserved regions encoding functional domains that are responsible for sequence-specific DNA-binding and heterodimerization with DP-family proteins. Association of E2Fs with one of the two DP proteins is necessary for high affinity, sequence-specific DNA binding, and in the case of E2F1-E2F5, binding to RB-family members (6,13). High-level expression of E2F or DP proteins can cause cell cycle progression and oncogenic transformation. Although the exact mechanism by which E2F activates transcription is still unknown, in vitro studies revealed that E2F1 can bind to TBP (14) and biochemical analysis showed an interaction between the transcriptional activation domain of E2F1 and CBP (15), potentially recruiting histone acetylase activity to the promoter. Overall, these studies argue that E2F plays a central role in orchestring cell cycle progression by integrating the processes that regulate G1/S phase transition with the transcription apparatus.
###end p 5
###begin p 6
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c16">16</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c20">20</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c21">21</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c22">22</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c16">16</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c20">20</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c23">23</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c24">24</xref>
###xml 555 558 555 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c19">19</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c25">25</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c27">27</xref>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c30">30</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c31">31</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c29">29</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c32">32</xref>
###xml 1148 1149 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c4">4</xref>
###xml 1150 1152 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c29">29</xref>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c33">33</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c19">19</xref>
###xml 1351 1353 1351 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c34">34</xref>
###xml 1354 1356 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c35">35</xref>
###xml 1384 1394 1384 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c36">36</xref>
###xml 1734 1736 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 711 726 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1260 1264 <span type="species:ncbi:10090">mice</span>
###xml 1384 1394 <span type="species:ncbi:7227">Drosophila</span>
Despite the clear importance in allowing cell cycle progression, several studies have suggested a role for E2F1 in apoptosis under conditions of deregulated expression, for example by deletion of RB (16-20). In mice, interference with the regulation of E2F1 provided by RB results in unregulated cell proliferation and apoptosis (21,22). In many cells the bulk of E2F1-induced apoptosis appears to be p53 dependent (16,20). Ectopic expression of E2F1 has been shown to lead to increased levels of p53 (23,24), as a result of E2F1-mediated induction of p19ARF that in turn blocks MDM2-associated degradation of p53 (19,25-27). However, E2F1-induced apoptosis occurs also independent of p53 in tissue culture and transgenic mice (8,28-30), and RB has been shown to protect p53-null cells from apoptosis in an E2F1-binding-dependent manner (31). Mapping studies revealed that the apoptotic functions of E2F1 in the absence of p53 requires the DNA-binding domain but not the transcriptional activation domain (28,29,32), suggesting that pro-apoptotic E2F1 target genes are activated by removal of E2F1/RB repression rather than direct transactivation (4,28,29,33). The role of E2F1 as a direct tumor suppressor was supported by the observation that E2F1-deficient mice show an impaired apoptotic function and increased incidence of cancer development (19,34,35). Overexpression of E2F in Drosophila revealed an induction of the 'reaper' gene, known as a regulator of cell death, which leads to apoptosis (36), implicating the existence of a number of E2F1-induced apoptosis genes also in mammalian cells. We have recently identified the p53-homolog p73 as a first target of p53-independent apoptosis, which is directly activated by E2F1 (37). Linking deregulated E2F1 activity to the activation of genes such as p73 might constitute a p53-independent, anti-tumorigenic safeguard mechanism that has direct implications for the development of novel anti-cancer therapeutics to treat cancer cells lacking functional p53.
###end p 6
###begin p 7
###xml 182 188 <span type="species:ncbi:10090">murine</span>
To search for p53-independently activated E2F1 target genes, we used p53-negative Saos-2 cells to establish a 4-hydroxytamoxifen (4-OHT)-inducible cell line by fusion of E2F1 to the murine estrogen receptor (ER) ligand binding domain which permits conditional activation of E2F1 and allows us to distinguish between direct and indirect targets. cDNA-microarray screens combined with RT-PCR analysis revealed novel E2F1 target genes involved in multiple cellular functions such as cell cycle control and growth regulation, apoptosis, angiogenesis, invasion and metastasis. These results provide insight into the basis for a better understanding of the role of E2F1 in tumorigenesis as a basis for the development of novel anti-cancer therapeutics.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Cell culture
###end title 9
###begin p 10
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 367 368 367 368 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 812 814 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c38">38</xref>
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 305 309 <span type="species:ncbi:9913">calf</span>
Retrovirally infected Saos-2 ER-E2F1 cells which have been described previously (37) and VH6 human primary foreskin fibroblasts (obtained from M. Roggendorf, University of Essen) were maintained in Dulbecco's modified Eagle medium (DMEM; Life Technologies, Karslruhe, Germany) supplemented with 10% fetal calf serum (FCS; Biochrom). Media were supplemented with 2 mM l-glutamine, 100 mg/ml penicillin and 100 U/ml streptomycin (LifeTechnologies, Berlin, Germany). For serum-starvation conditions cells were grown in media containig 0.1% FCS for 24 h. E2F1 activity was induced by the addition of 4-OHT at a final concentration of 1 microM or by fresh media containing 15% FCS. Cycloheximide (CHX; Sigma) was used at a final concentration of 10 microg/ml. VH6 fibroblasts were infected by AdER-E2F1 as described (38).
###end p 10
###begin title 11
Microarray analysis
###end title 11
###begin p 12
###xml 196 197 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 300 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">33</sup>
###xml 438 443 <span type="species:ncbi:9606">Human</span>
For microarray analysis total RNA was extracted from Saos-2 ER-E2F1 cells treated for 8 h with either 1 microM 4-OHT or ethanol as a control using RNeasy Mini Kit (Qiagen, Hilden, Germany). Poly(A+) RNA was purified with Oligotextrade mark (Qiagen). For hybridization the probes were labeled with [33P]dATP using the Strip-EZtrade mark RT kit according to the manufacturer's protocol (Ambion, Austin, TX). Finally, two identical filters (Human LifeGridtrade mark 1.0) were hybridized according to the supplier's protocol (Incyte Genomics, Palo Alto, CA). The labeling efficiency was determined using a Tri-Carb 2100 TR (Canberra-Packard GmbH; Dreieich, Gemany) scintillation counter and calculated as suggested by Incyte Genomics. Images were obtained on a Fujifilm BAS-1500 scanner and analysis was performed by Incyte Genomics using ArrayVision software.
###end p 12
###begin title 13
Immunofluorescence
###end title 13
###begin p 14
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 414 418 <span type="species:ncbi:9925">goat</span>
###xml 424 429 <span type="species:ncbi:10090">mouse</span>
Cells were grown on coverslips to 60-80% confluence. Cell were serum-starved for 24 h, activation of the ER-E2F1 fusion protein was induced by 4-OHT for 8 h. For E2F1 staining, cells were subsequently fixed and permeabilized in -20degreesC cold methanol for 10 min. Coverslips were air dried and stained with the mouse monoclonal anti-HA antibody F-7 (Santa Cruz Biotechnology, Heidelberg, Germany), followed by a goat anti-mouse Cy3-conjugated antibody (Jackson ImmunoResearch Laboratories, Dianova, Hamburg, Germany).
###end p 14
###begin title 15
Semi-quantitative RT-PCR
###end title 15
###begin p 16
###xml 238 240 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
RT-PCR was performed on total RNA prepared by RNeasy Mini Kit (Qiagen). Following DNase I treatment, 1 microg RNA was reverse transcribed using Omniscript RT (Qiagen) and Oligo-dT. PCR amplification was performed as described previously (37). A minimum amount of cycles was carried out to stay within the linear amplification process. Used primer sequences can be obtained on request.
###end p 16
###begin title 17
Flow cytometry
###end title 17
###begin p 18
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c38">38</xref>
For flow cytometry ER-E2F1-expressing Saos-2 cells were incubated in the absence or presence of 1 mM 4-OHT. Cells were harvested 48 h after induction, fixed in 70% ethanol and stained for DNA content with propidium iodide. Flow cytometric analysis was carried out (FACSVantage, Becton Dickinson) and analyzed as described (38) using CellQuest software (Becton Dickinson).
###end p 18
###begin title 19
RESULTS
###end title 19
###begin title 20
Characterization of the Saos-2 ER-E2F1-inducible cell line
###end title 20
###begin p 21
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c40">40</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c38">38</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c39">39</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 933 934 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 1197 1198 1197 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 1356 1357 1356 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 1501 1502 1501 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
###xml 1747 1752 1747 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 1755 1756 1755 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 1757 1758 1757 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 1790 1794 1790 1794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 1833 1835 1833 1835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 1836 1838 1836 1838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c41">41</xref>
###xml 1956 1957 1956 1957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f1">1</xref>
We and others have previously shown that the post-translational regulation of E2F1 by fusion to the hormone-binding domain of the ER is a useful technique to analyze the functional consequences of deregulated E2F1 expression (37-40). The ER-E2F1 fusion protein is inactive in the absence of the synthetic ligand 4-OHT and becomes rapidly activated after addition of 4-OHT by allowing translocation from the cytosol to the nucleus (38,39). To identify E2F1 target genes, we generated a 4-OHT-inducible Saos-2 cell line by infection with a retrovirus encoding ER-E2F1 (37) (Fig. 1A). Ligand-dependent activation of E2F1 in the Saos-2 cell line was initially tested by immunofluorescence analyis of the subcellular localization of ER-E2F1. As shown in Figure 1B (top left), in the absence of ligand the fusion protein is located in the cytoplasm, while 8 h after addition of 4-OHT, ER-E2F1 was exclusively detected in the nucleus (Fig. 1B, top right), indicating that the ER-E2F1 fusion protein is correctly translocated from the cytosol to the nucleus upon activation. After 48 h of induction, morphological changes were observed only in the presence of 4-OHT, with cells rounding up at day 2 (Fig. 1B, middle right), characteristic for cells undergoing apoptosis. Flow cytometry analysis showed an increasing amount of cells with a sub-G1 DNA content (Fig. 1B, bottom right), indicative of apoptosis, whereas in the absence of 4-OHT, no significant increase in the sub-G1 population was observed (Fig. 1B, bottom left). Next, we determined whether E2F1 expression upon activation of the inducible Saos-2 cell line leads to the up-regulation of known E2F1 target genes. Semi-quantitative RT-PCR analysis revealed a strong mRNA increase of cyclin E (CCNE1) (6,8) and of the pro-apoptotic gene TP73, recently shown to be an E2F1 target (37,41). Expression was detected as early as 4 h after induction, reaching maximum levels by 8 h following activation (Fig. 1C). Based on these data, we have chosen the 8-h time point as the optimum duration of 4-OHT treatment before isolation of RNA for array hybridization.
###end p 21
###begin title 22
Identification of novel E2F1-regulated target genes
###end title 22
###begin p 23
###xml 750 755 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 757 762 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE2</italic>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K5</italic>
###xml 1034 1035 1010 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gkf267tb1">1</xref>
###xml 347 352 <span type="species:ncbi:9606">Human</span>
Given the central role of E2F in tumorigenesis, further elucidation of E2F1-regulated targets will help to better understand the molecular scenario controlled by E2F1 and possibly provide the basis for the identification of novel gene therapeutics for anti-cancer treatment. To assess changes in mRNA expression after E2F1 activation, we used the Human LifeGrid 1.0 cDNA microarray carrying 8400 cDNAs and ESTs. For microarray analysis, hybridization probes were prepared from total RNA isolated from Saos-2 ER-E2F1 cells treated for 8 h with 4-OHT or untreated cells as a control. We found that 470 genes were significantly up-regulated in Saos-2 cells following E2F1 activation. From these genes, we randomly selected four known E2F1 target genes (CCND1, CCNE1, CCNE2 and MAP3K5) as internal controls, and 30 additional potentially E2F1-regulated genes representing a spectrum from moderately activated (approximately2-fold increase) to strongly activated (approximately30-fold induction) for verification analysis by RT-PCR (Table 1).
###end p 23
###begin title 24
Verification of microarray analysis by RT-PCR
###end title 24
###begin p 25
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gkf267tb1">1</xref>
###xml 526 529 526 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CLU</italic>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRADD</italic>
###xml 538 541 538 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAT</italic>
###xml 543 558 543 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DMA, MAPK12</italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPK14</italic>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 775 782 775 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIA0767</italic>
###xml 784 791 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIA0455</italic>
###xml 793 798 793 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 800 805 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 807 814 807 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 816 821 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 823 827 823 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF-2</italic>
###xml 836 841 836 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNA2</italic>
###xml 843 847 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAK1</italic>
###xml 849 853 849 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAWR</italic>
###xml 855 858 855 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAD</italic>
###xml 863 866 863 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BID</italic>
This group of known and putative E2F1-regulated genes was confirmed by RT-PCR using gene-specific primers. For RT-PCR total RNA was prepared from the ER-E2F1 expressing Saos-2 cell line at 0, 4, 8 and 24 h after 4-OHT treatment. All of the known target genes and 24 of the 30 randomly selected putative genes (80%) that showed increased expression levels in the microarray screen were confirmed as significantly up-regulated by E2F1 (mRNA levels of 13 representative targets are shown in Fig. 2; see also Table 1). Six genes (CLU, CRADD, FAT, HLA-DMA, MAPK12 and MAPK14) could not be verified by RT-PCR. As shown in Figure 2, the fold induction of gene expression as calculated by the ArrayVision software parallels the levels of induction observed by RT-PCR as detected for KIA0767, KIA0455, RAD52, STK15, MAP3K14, MMP16, RFC3, FGF-2, IFNA2, BAK1, PAWR, BAD and BID at 8 h after ER-E2F1 activation. None of the genes with an induction of <2-fold in the microarray screen could be verified as an E2F1 target gene by RT-PCR, suggesting that a cut-off of 2-fold is a reliable limit to ensure a maximum number of positive genes.
###end p 25
###begin title 26
Selection of direct and indirect E2F1 targets
###end title 26
###begin p 27
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f3">3</xref>
###xml 616 624 616 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0455</italic>
###xml 626 631 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 884 889 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 895 899 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 901 902 901 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 903 904 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c8">8</xref>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 969 977 969 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0767</italic>
###xml 979 984 979 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 989 996 989 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 1122 1123 1122 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f3">3</xref>
As an advantage of the post-translational regulatory system, it enables us to measure the effect of E2F1 activation in the absence of de novo protein synthesis, thus allowing the identification of directly activated transcripts (8). To test whether the genes identified as E2F1 targets are directly or indirectly regulated by E2F1, we performed RT-PCR on ER-E2F1-expressing Saos-2 cells grown in the presence of the protein synthesis inhibitor CHX alone, CHX plus 4-OHT or 4-OHT alone. An analysis of a subset of genes is shown in Figure 3. By addition of 4-OHT, no increase in expression intensity was observed for KIAA0455, STK15, MMP16 and RFC3 in cells grown in the presence of CHX, suggesting that in these cases E2F1-induced synthesis of other proteins is required for the stimulation of gene expression (compare lanes 2 and 4). As shown for the primary E2F1 targets, cyclin E (CCNE1) and TP73 (6,8,37), a significant induction of RNA expression was observed for KIAA0767, RAD52 and MAP3K14 by addition of 4-OHT even in the presence of CHX. Based on these data, these genes appear to be direct targets of E2F1 (Fig. 3). However, the addition of CHX alone leads to an increase in mRNA levels, which is consistent with previous data and is most likely due to a stabilization of RNA.
###end p 27
###begin title 28
Effect of E2F1 in primary cells and by endogenous E2F1
###end title 28
###begin p 29
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c38">38</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f4">4</xref>
###xml 1030 1031 1030 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f5">5</xref>
To exclude that the effects seen with overexpressed E2F1 in Saos-2 cells are limited to this system or tumor cells, we infected primary VH6 fibroblasts with an adenoviral vector encoding the ER-E2F1 fusion protein as described previously (38). Subsequently, RT-PCR was performed on infected fibroblasts that had been serum starved and then induced with 4-OHT using primers for a subset of genes that were found to be up-regulated by ER-E2F1 in Saos-2 cells (Fig. 4). In summary, 9 of 11 selected genes induced by Saos-2 ER-E2F1 cells were also significantly up-regulated in primary cells, implying that E2F1 has a general impact on gene expression independent of whether or not cells are transformed, resulting in the modulation of a common pattern of targets. Moreover, to ensure that the identified targets are not an effect of E2F1 overexpression but can also be induced by endogenous E2F1 levels, transcripts were analyzed in Saos-2 ER-E2F1 cells grown in the absence of serum and following serum induction with 15% FCS (Fig. 5). As shown for all target genes analyzed, expression can be substantially induced by serum to levels comparable with the fold changes calculated from the array screen following ER-E2F1 activation by 4-OHT. However, it should be mentioned that the serum induction experiment provides a hint, but certainly no firm evidence, that the identified genes are regulated by endogenous E2F1 proteins.
###end p 29
###begin title 30
E2F1 regulates genes with multiple cellular functions
###end title 30
###begin p 31
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c29">29</xref>
###xml 321 328 321 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARHGAP4</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 343 348 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFSF9</italic>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAD</italic>
###xml 506 509 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BID</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAK1</italic>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAWR</italic>
###xml 598 605 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFLAR</italic>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF-2</italic>
###xml 958 964 958 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF-B</italic>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 978 979 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f4">4</xref>
###xml 1050 1055 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 1077 1078 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 1080 1081 1080 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f3">3</xref>
###xml 1086 1087 1086 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f5">5</xref>
###xml 1196 1197 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gkf267tb1">1</xref>
E2F plays an essential role in monitoring conditions of cell cycle progression, but also has apoptotic activity in response to perturbation of normal cell proliferation, consistent with its tumor suppressor function (6,28,29). Among the genes known to be involved in cell cycle control and DNA replication, we identified ARHGAP4, RFC3, RAD52, STK15 and TNFSF9 as E2F1 target genes. Regarding the role of E2F1 in apoptosis, we found that cellular factors such as the pro-apoptotic Bcl-2 family members BAD, BID and BAK1, or the PRKC apoptosis WT1 regulator PAWR, as well as the apoptosis inhibitors MAP3K14 (Fig. 2) and CFLAR (FLIP) might be involved in E2F1-regulated death. Besides these regulatory properties, our study supports the idea that E2F1 fulfils additional cellular functions important for tumorigenesis. For example, several genes associated with the process of angiogenesis showed an increased expression following E2F1 activation (e.g. FGF-2, VEGF-B) (Figs 2 and 4). Another interesting E2F1 target gene is the matrixmetalloproteinase MMP16, as shown in Figures 2, 3 and 5. Twenty-nine verified E2F1 target genes classified according to their cellular functions are shown in Table 1. To be undoubtedly verified as an E2F target, however, our findings by microarray analysis and RT-PCR have to be confirmed by other methods such as chromatin immunoprecipitation (ChIP) in preferentially primary untransfected cells.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c6">6</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c7">7</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c16">16</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c18">18</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c29">29</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c41">41</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c42">42</xref>
Over the past decade, a large number of studies revealed the central role of the RB pathway in the regulation of G1/S transition and the control of cell proliferation by modulating the activity of the transcription factor E2F. From these studies it has become clear that E2F drives cell cycle progression through the induction of S-phase genes that encode cell cycle regulatory functions and DNA replication activities (6,7). In addition, it has been shown that the RB pathway is linked to events involved in an anti-tumor safeguard mechanism through the induction of apoptosis which is largely mediated by E2F1. E2F1 promotes apoptosis in several systems, either in association with p53 (16,18) or independent of p53 (28,29). Our group and others have recently shown that part of the apoptotic activity of E2F1 reflects the ability to induce p73 transcription (37,41,42). However, given the important role of individual activities within the pathway affecting cell growth control and cancer development, it is reasonable to assume that E2F1 likely participates in additional cellular functions, implying that the majority of E2F1 target genes is still unknown.
###end p 33
###begin p 34
Supporting this view, our cDNA microarray screen using RNA from a 4-OHT-inducible Saos-2 cell line as a probe revealed that increased E2F1 activity leads to the induction of the expression of a large number of genes. These include genes that encode cell cycle regulatory activities and those which are involved in DNA replication and DNA repair. Moreover, from our analysis it becomes clear that E2F1 is specifically involved in additional cellular activities such as apoptosis and angiogenesis, as well as in the process of invasion and metastasis. We found that increased expression of E2F1 in Saos-2 cells resulted in a reproducible up-regulation of 24 genes, so far not known as E2F1-regulated targets.
###end p 34
###begin p 35
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c43">43</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c45">45</xref>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE2</italic>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c40">40</xref>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 832 835 832 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC</italic>
###xml 1072 1074 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c46">46</xref>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c47">47</xref>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c46">46</xref>
###xml 1469 1473 1469 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC4</italic>
###xml 1603 1605 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c48">48</xref>
###xml 1719 1720 1719 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c5">5</xref>
###xml 1743 1748 1743 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 2041 2043 2041 2043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c49">49</xref>
###xml 606 611 <span type="species:ncbi:9606">human</span>
###xml 804 809 <span type="species:ncbi:9606">human</span>
###xml 1583 1586 <span type="species:ncbi:10116">rat</span>
A variety of results pointed to E2F1 as a critical determinant of the G1/S-phase transition during the cell cycle. E2F1 directly transactivates genes that are necessary for DNA synthesis, and promotes cell cycle progression via the induction of cyclin D1 (CCND1) and cyclin E (CCNE1) (43-45). The expression of both genes was also found to be induced in our screen following E2F1 activation. Besides these known E2F1 targets involved in cell cycle regulation, we detected an increase in the expression of cyclin E2 (CCNE2), which has recently been shown to be up-regulated by all three E2Fs (E2F1-E2F3) in human U2OS cells (40). In addition, we identified several novel target genes coding for components of the DNA replication and/or repair machinery [e.g. replication factor C 3 (RFC3) and RAD52]. The human replication factor C (RFC) is a five-subunit DNA polymerase accessory protein that functions as a structure-specific, DNA-dependent ATPase. Through the action of RFC, the proliferating cell nuclear antigen (PCNA) is loaded onto DNA in an ATP-dependent reaction (46,47). A previous analysis of the interaction between the five subunits suggested a cooperative mechanism in the assembly of the RFC complex between a three-subunit core complex, consisting of p36, p37 and p40, and the large p140 subunit (46). From this study it appears that the RFC3 p38 subunit, which we identified as a target of E2F1, is essential for the core/p140 interaction. In addition, RFC4, coding for the 37 kDa core subunit of RFC, was recently described as an E2F1-regulated gene in Zinc induced rat-1a fibroblasts (48). Moreover, it has been suggested that E2F1 is involved in various DNA repair activities by, for example, RAD51 (5). Here, we identified RAD52 as a direct target for the E2F transcription factor 1. The DNA damage repair protein RAD52 binds specifically to single-stranded tails present at sites of resected double-strand breaks (DSBs) and is known to play an important role in the early stages of genetic recombination and DSB repair (49). Given the number of known replication-related E2F1 targets, our data support the idea that virtually the entire process involved in the regulation of the G1/S transition and the activation of DNA replication is under the control of the RB/E2F pathway.
###end p 35
###begin p 36
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c50">50</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c51">51</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BTAK</italic>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c52">52</xref>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 1054 1055 1054 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c3">3</xref>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c5">5</xref>
###xml 1101 1106 1101 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 648 653 <span type="species:ncbi:9606">human</span>
###xml 1039 1044 <span type="species:ncbi:9606">human</span>
Furthermore, the E2F1 protein can act as an oncogene and participates in transformation (50). Viewed in the context of abnormal proliferation and transformation, centrosome duplication is a key requirement for correct segregation of chromosomes during cell division. A previous study indicated that centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A (51). Interestingly, in our cDNA screen the expression of STK15 (also known as BTAK and aurora2), encoding a critical centrosome associated serine/threonine kinase, was found to be strongly induced by E2F1. STK15 amplification has been previously detected in multiple human cancer cell lines and primary tumors, and overexpression was shown to be associated with the induction of centrosome duplication-distribution abnormalities, aneuploidy and transformation (52). However, we did not observe an increase in expression intensity in the presence of CHX, suggesting that STK15 is an indirect target of E2F1. Since the RB pathway is disrupted in virtually all human cancers (3,5), deregulated E2F1 activity and subsequent STK15-induced centrosome amplification may contribute to the loss of cell growth control and development of cancer.
###end p 36
###begin p 37
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c16">16</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c18">18</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c28">28</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c29">29</xref>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c27">27</xref>
###xml 603 605 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c53">53</xref>
###xml 731 733 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c37">37</xref>
###xml 734 736 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c41">41</xref>
###xml 1035 1038 1031 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAD</italic>
###xml 1040 1044 1036 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAK1</italic>
###xml 1049 1052 1045 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BID</italic>
###xml 1102 1107 1098 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFLAR</italic>
###xml 1150 1154 1146 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAWR</italic>
###xml 1161 1168 1157 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 1278 1279 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 1349 1350 1341 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1356 1357 1348 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1414 1416 1406 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c40">40</xref>
###xml 1457 1458 1449 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1477 1479 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c54">54</xref>
###xml 1636 1637 1628 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1853 1854 1845 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2039 2041 2031 2033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c55">55</xref>
###xml 2208 2210 2196 2198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c53">53</xref>
In addition, under deregulated conditions the activity of E2F1 is linked to events that determine cell fate through induction of apoptosis, thus protecting the organism against oncogenic transformation. Many studies have shown that E2F1 promotes apoptosis in several systems, either in association with p53 or alone (16,18,28,29). Three mechanisms of E2F1-induced apoptosis have been described so far: (i) activation of the CDKN2A transcript p14ARF, resulting in p53-dependent apoptosis (27); (ii) inhibition of survival signals, making tumor cells more sensitive to apoptotic signals such as TNFalpha (53); and (iii) induction of p73 expression, leading to the activation of p53-responsive target genes and programmed cell death (37,41). Although p73 has been discovered as a first target, it does not fully account for E2F1-induced death in a p53-negative system. Using RNA from inducible Saos-2 cells which are negative for p53, we detected an increase of six apoptosis related genes, such as the pro-apoptotic Bcl-2 family members BAD, BAK1 and BID, the caspase-8 and FADD-like apoptosis regulator CFLAR (FLIP), the PRKC apoptosis WT1 regulator (PAWR), and MAP3K14, also known as the NF-kappaB-inducing kinase (NIK) which had not been described as E2F1 targets before (Fig. 2). Together with the previous finding, indicating that the cytochrome c (cyt c)-binding protein Apaf1 is a target for the E2F1 factor (40), which can activate caspase-9 in a cyt c-dependent manner (54), our data clearly suggest a central role for E2F1 in apoptosis by both the mitochondrial pathway and the death receptor pathway through (i) release of cyt c from the mitochondria by regulating pro-apoptotic members of the Bcl-2 family; (ii) induction of the caspase-8 substrate BID, which amplifies death-receptor signaling via the mitochondria, resulting in enhanced cyt c release; and (iii) upon inhibition of death-receptor-mediated apoptosis by inducing the cellular FLICE-inhibitory protein (FLIP), which protects cells from procaspase-8-induced death (55). As mentioned above, deregulated E2F1 activity has previously been linked to TRAF2 degradation, leading to the inhibition of anti-apoptotic signaling via NF-kappaB (53). Interestingly, we identified the TRAF2-interacting protein NIK as a direct target of E2F1, thereby linking increased NIK activity to the inhibition of anti-apoptotic TNF-receptor signaling. Thus, it will be interesting to analyze whether increased NIK activity is responsible for TRAF2 degradation.
###end p 37
###begin p 38
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c56">56</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c57">57</xref>
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c58">58</xref>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 444 451 444 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT3-MMP</italic>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f2">2</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf267f3">3</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c59">59</xref>
With regard to recent reports studying the role of E2F1 in tumor progression, it has been shown that overexpression of E2F1 is associated with increased tumor cell invasiveness and metastatic progression (56,57). Moreover, expression of the RB tumor suppressor gene inhibits tumor cell invasion in vitro (58). Here, we provide evidence that E2F1 indirectly up-regulates the expression of the membrane-type matrix metalloproteinase 16 (MMP16 or MT3-MMP) (Figs 2 and 3) which belongs to the group of MT-MMPs that activate MMP-2, a key regulator of invasion and metastasis (59).
###end p 38
###begin p 39
###xml 217 222 217 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 350 357 350 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c60">60</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c61">61</xref>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c62">62</xref>
Furthermore, angiogenesis is an essential step in tumor progression. Thus, it has been speculated that the angiogenic phenotype may involve the inactivation of the RB-pathway related tumor suppressor genes such as p16INK4a and p53. Viewed in the above context, induction of the RB-related protein p130 was previously observed to inhibit angiogenesis in vivo, correlating with the down-regulation of vascular endothelial growth factor (VEGF) expression (60). In agreement, we found a significant induction in the expression of the vascular endothelial growth factor-B (VEGF-B), an effector of blood vessel growth during development and disease (61), and the fibroblast growth factor-2 (FGF-2), strongly suggesting an additional role of E2F1 in angiogenesis. It is interesting to note that the adenovirus E1A protein, which promotes cellular proliferation by deregulation of the RB pathway, stimulates FGF-2 production and promotes differentiation of primary endothelial cells (62).
###end p 39
###begin p 40
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c63">63</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c64">64</xref>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in&#160;vivo</italic>
###xml 545 554 545 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
###xml 558 565 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c40">40</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c48">48</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c65">65</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c65">65</xref>
###xml 886 892 886 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c48">48</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c65">65</xref>
###xml 933 936 <span type="species:ncbi:10116">Rat</span>
###xml 984 990 <span type="species:ncbi:10090">murine</span>
###xml 1126 1131 <span type="species:ncbi:9606">human</span>
Given the critical role of E2F for normal cell proliferation and tumorigenesis, a number of recent studies were aimed at identifying E2F target genes on a genome-wide scale. Whereas Kel et al. (63) used a computer-assisted approach to identify E2F-regulated promoters based on screening genome databases for sequences with high homology to an E2F consensus site, Weinmann et al. (64) cloned novel E2F target promoters by use of ChIP as an unbiased, in vivo approach. In contrast to these studies, which identified E2F-binding genomic sequences (in silico or in vivo), several other groups used DNA microarray analysis to identify E2F-regulated genes (40,48,65). The strength of this latter approach lies in the ability to assay a very large number of potential targets in an unbiased manner (65). However, all groups have used different strategies to induce E2F activity. Whereas Kalma et al. (48) used Zinc-inducible E2F-expressing Rat-1 fibroblasts, Ishida and colleagues (65) used murine cells in which high-level E2F expression was obtained by infection with adenoviral vectors. In contrast, we regulated E2F1 activity in human cells on a post-translational level to allow classification of identified targets as direct or indirect. However, despite considerable differences in the experimental approaches and cellular systems used, there appears to be substantial overlap in the identified target genes. Although every single study has its methodical limitations and needs to be considered with appropriate caution, the sum of all data underlines the strength of microarray-based analyses to define the gene regulatory function of a specific transcription factor such as E2F1.
###end p 40
###begin p 41
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf267c66">66</xref>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 739 744 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 785 790 785 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
As a key regulator of cell cycle progression, E2F drives cells into the cell cycle, thereby activating a number of cell cycle regulated genes. These can be genes that are directly induced by E2F1, such as cyclin E (CCNE1), where E2F1 binds directly to the Cyclin E promoter (66). Furthermore, E2F1 up-regulation results in the activation of other transcription factors such as c-myc, which in turn lead to the induction of a variety of 'secondary' genes, so-called indirect targets of E2F1. As an advantage of our approach we are able to discriminate direct and indirect targets by analyzing induction in the presence of CHX which inhibits the activation of indirect target genes. In our experimental setting, we found direct (e.g. RAD52, CCNE1) as well as indirect E2F1 targets (e.g. MMP16).
###end p 41
###begin p 42
###xml 469 474 <span type="species:ncbi:9606">human</span>
###xml 574 579 <span type="species:ncbi:9606">human</span>
In summary, our present analysis provides a spectrum of novel E2F1 target genes involved in multiple cellular functions which are known to be E2F1 regulated such as cell cycle control, DNA replication and apoptosis. In addition, the identification of novel E2F1 target genes participating in the processes of angiogenesis, invasion and metastasis supports the view that E2F1 plays a central role in many aspects of cancer development. Given the fact that virtually all human tumors exhibit alterations in the RB pathway, understanding the role of E2F1 in the development of human malignancies will have a profound impact on the understanding of normal cell growth and possibly on the development of novel anti-cancer therapeutics.
###end p 42
###begin title 43
Figures and Tables
###end title 43
###begin p 44
###xml 73 74 73 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 259 260 259 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 724 725 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 753 754 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 763 764 763 764 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 813 819 813 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1)</italic>
###xml 821 825 821 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 830 835 830 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
 Regulation of E2F1 activity in the inducible Saos-2 ER-E2F1 cell line. (A) Schematic model of ER-E2F1 induction by 4-OHT. Upon ligand-dependent activation of ER-E2F1, constitutively expressed fusion proteins translocate from the cytoplasm into the nucleus. (B) Functional characterization of the inducible system. Cells were grown for 8 h (immunofluorescence) and 48 h (morphology and FACS), respectively, in the absence or presence of 4-OHT. Nuclear localization (top) was determined by using an anti-HA antibody (F-7). Induction of E2F1 is associated with morphological changes (middle) and by accumulation of cells with a sub-G1 DNA content in FACS analysis consistent with apoptosis. FACS profiles showing DNA content (x-axis) against cell number (y-axis). (C) Semi-quantitative RT-PCR analysis of cyclin E (CCNE1), TP73 and GAPDH mRNA levels in serum-starved Saos-2 ER-E2F1 grown in the presence of 4-OHT for the time indicated.
###end p 44
###begin p 45
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
 Verification of microarray analysis by RT-PCR. Serum-starved Saos-2 cells stably transfected with ER-E2F1 were grown in the presence of 4-OHT for the time indicated. Semi-quantitative RT-PCR analysis of potential E2F1 targets including TP73 as a control and GAPDH expression was carried out under linear amplification conditions.
###end p 45
###begin p 46
###xml 272 280 272 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0455</italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0767</italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 354 361 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
 Classification of E2F1 targets as direct and indirect. Semi-quantitative RT-PCR analysis of different E2F1 regulated genes in serum-starved Saos-2 cells expressing ER-E2F1 grown in the presence of 4-OHT and/or CHX as indicated. All targets are shown 4 h after induction. KIAA0455, STK15, MMP16 and RFC3 are indirect targets, whereas KIAA0767, RAD52 and MAP3K14, as well as the controls TP73 and CCNE1 are direct targets. PCR products were quantified in relative software units by the Bio-Imaging-Analyzer (Fuji) using the TINA program version 2.09 (shown as fold induction). The data were normalized to GAPDH values and the untreated control was set as 1.
###end p 46
###begin p 47
###xml 97 105 97 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0767</italic>
###xml 107 115 107 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0455</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD52</italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK15</italic>
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAP3K14</italic>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP16</italic>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC3</italic>
###xml 153 161 153 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARGHGAP4</italic>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF-B</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
 E2F1-induced changes in transcript levels in normal cells. Semi-quantitative RT-PCR analysis of KIAA0767, KIAA0455, RAD52, STK15, MAP3K14, MMP16, RFC3, ARGHGAP4 and VEGF-B expression in VH6 fibroblasts. Cells were serum-starved, infected with 100 MOI of AdERE2F-1, and grown in the presence of 4-OHT for indicated time points. TP73 was used as a positive control.
###end p 47
###begin p 48
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
 Activation of endogenous E2F1 is sufficient to induce target genes. Semi-quantitative RT-PCR analysis on total RNA of candidate E2F1 target genes (and TP73 as a control) following induction of endogenous E2F1 with serum. Cells were serum-starved for 24 h and subsequently grown in the presence of 15% FCS as indicated.
###end p 48
###begin title 49
Classification of E2F1 target genes verified by RT-PCR
###end title 49
###begin p 50
GenBank numbers are as given by the array supplier. Unigene entries and gene symbols are given as found at http://www.ncbi.nlm.nih.gov/UniGene
###end p 50
###begin p 51
+/- 4-OHT ratio refers to the microarray measurements; d, direct target; i, indirect target; n.d., not determined; n.a., not applicable.
###end p 51
###begin p 52
*TP73 was not present on the microarray; it has been used a positive control for verification experiments.
###end p 52
###begin title 53
ACKNOWLEDGEMENT
###end title 53
###begin p 54
This work was supported by grant 10-1411-PuI of the Deutsche Krebshilfe (B.M.P.).
###end p 54
###begin title 55
REFERENCES
###end title 55

